You are here: Industry Insights > Antabio

News List

Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections PharmaSources
October 14, 2024
Antabio’s MEM-ANT3310 is a next generation broad-spectrum antibacterial combination that has been designed to address the growing problem of antimicrobial resistance in severe hospital infections.
ANTABIO Raises €25 Million in Series B Financing B3C newswire
December 13, 2023
Antabio SAS announced today that it has raised €25m in a series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from the company’s historical investors including BNP Paribas Développement.
ANTABIO Completes € 12.5M Series A b3cnewswire
July 24, 2018
New investors Omnes, BNP Paribas Développement and Sham Innovation Santé invest an additional €5.2M on top of the €7.3M first closing announced in October 2017
ANTABIO Raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-Neg b3cnewswire
October 17, 2017
The Series A Complements Recent CARB-X Grant of up to $8,9 Million
Antabio to develop treatment for Pseudomonas infections in cystic fibrosis patients pharmaceutical-technology
July 27, 2017
French biopharmaceutical company Antabio has secured a non-dilutive funding to accelerate the development of a new small molecule drug to treat chronic Pseudomonas infections in cystic fibrosis patients.